347 related articles for article (PubMed ID: 32394479)
21. Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus.
Huynh H; Hao HX; Chan SL; Chen D; Ong R; Soo KC; Pochanard P; Yang D; Ruddy D; Liu M; Derti A; Balak MN; Palmer MR; Wang Y; Lee BH; Sellami D; Zhu AX; Schlegel R; Huang A
Mol Cancer Ther; 2015 May; 14(5):1224-35. PubMed ID: 25724664
[TBL] [Abstract][Full Text] [Related]
22. New Insights Into the Role of mTOR Signaling in the Cardiovascular System.
Sciarretta S; Forte M; Frati G; Sadoshima J
Circ Res; 2018 Feb; 122(3):489-505. PubMed ID: 29420210
[TBL] [Abstract][Full Text] [Related]
23. Diverse signaling mechanisms of mTOR complexes: mTORC1 and mTORC2 in forming a formidable relationship.
Jhanwar-Uniyal M; Wainwright JV; Mohan AL; Tobias ME; Murali R; Gandhi CD; Schmidt MH
Adv Biol Regul; 2019 May; 72():51-62. PubMed ID: 31010692
[TBL] [Abstract][Full Text] [Related]
24. Targeting the mTOR pathway in hepatocellular carcinoma: current state and future trends.
Matter MS; Decaens T; Andersen JB; Thorgeirsson SS
J Hepatol; 2014 Apr; 60(4):855-65. PubMed ID: 24308993
[TBL] [Abstract][Full Text] [Related]
25. CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization.
Mortensen DS; Fultz KE; Xu S; Xu W; Packard G; Khambatta G; Gamez JC; Leisten J; Zhao J; Apuy J; Ghoreishi K; Hickman M; Narla RK; Bissonette R; Richardson S; Peng SX; Perrin-Ninkovic S; Tran T; Shi T; Yang WQ; Tong Z; Cathers BE; Moghaddam MF; Canan SS; Worland P; Sankar S; Raymon HK
Mol Cancer Ther; 2015 Jun; 14(6):1295-305. PubMed ID: 25855786
[TBL] [Abstract][Full Text] [Related]
26. mTORC1 and mTORC2 in cancer and the tumor microenvironment.
Kim LC; Cook RS; Chen J
Oncogene; 2017 Apr; 36(16):2191-2201. PubMed ID: 27748764
[TBL] [Abstract][Full Text] [Related]
27. Synergistic Effects between mTOR Complex 1/2 and Glycolysis Inhibitors in Non-Small-Cell Lung Carcinoma Cells.
Jiang S; Zou Z; Nie P; Wen R; Xiao Y; Tang J
PLoS One; 2015; 10(7):e0132880. PubMed ID: 26176608
[TBL] [Abstract][Full Text] [Related]
28. Genetic and pharmacologic evidence that mTOR targeting outweighs mTORC1 inhibition as an antimyeloma strategy.
Chen X; Díaz-Rodríguez E; Ocio EM; Paiva B; Mortensen DS; Lopez-Girona A; Chopra R; Miguel JS; Pandiella A
Mol Cancer Ther; 2014 Feb; 13(2):504-16. PubMed ID: 24431075
[TBL] [Abstract][Full Text] [Related]
29. mTOR regulates aerobic glycolysis through NEAT1 and nuclear paraspeckle-mediated mechanism in hepatocellular carcinoma.
Zhang H; Su X; Burley SK; Zheng XFS
Theranostics; 2022; 12(7):3518-3533. PubMed ID: 35547764
[No Abstract] [Full Text] [Related]
30. Current development of the second generation of mTOR inhibitors as anticancer agents.
Zhou HY; Huang SL
Chin J Cancer; 2012 Jan; 31(1):8-18. PubMed ID: 22059905
[TBL] [Abstract][Full Text] [Related]
31. Canonical signaling and nuclear activity of mTOR-a teamwork effort to regulate metabolism and cell growth.
Giguère V
FEBS J; 2018 May; 285(9):1572-1588. PubMed ID: 29337437
[TBL] [Abstract][Full Text] [Related]
32. Dual targeting of mTORC1/C2 complexes enhances histone deacetylase inhibitor-mediated anti-tumor efficacy in primary HCC cancer in vitro and in vivo.
Shao H; Gao C; Tang H; Zhang H; Roberts LR; Hylander BL; Repasky EA; Ma WW; Qiu J; Adjei AA; Dy GK; Yu C
J Hepatol; 2012 Jan; 56(1):176-83. PubMed ID: 21835141
[TBL] [Abstract][Full Text] [Related]
33. Nutrient signaling to mTOR and cell growth.
Jewell JL; Guan KL
Trends Biochem Sci; 2013 May; 38(5):233-42. PubMed ID: 23465396
[TBL] [Abstract][Full Text] [Related]
34. Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.
Serova M; de Gramont A; Tijeras-Raballand A; Dos Santos C; Riveiro ME; Slimane K; Faivre S; Raymond E
Cancer Chemother Pharmacol; 2013 May; 71(5):1297-307. PubMed ID: 23479136
[TBL] [Abstract][Full Text] [Related]
35. The mTORC2-Akt1 Cascade Is Crucial for c-Myc to Promote Hepatocarcinogenesis in Mice and Humans.
Xu Z; Xu M; Liu P; Zhang S; Shang R; Qiao Y; Che L; Ribback S; Cigliano A; Evert K; Pascale RM; Dombrowski F; Evert M; Chen X; Calvisi DF; Chen X
Hepatology; 2019 Nov; 70(5):1600-1613. PubMed ID: 31062368
[TBL] [Abstract][Full Text] [Related]
36. Heat Stress-Induced PI3K/mTORC2-Dependent AKT Signaling Is a Central Mediator of Hepatocellular Carcinoma Survival to Thermal Ablation Induced Heat Stress.
Thompson SM; Callstrom MR; Jondal DE; Butters KA; Knudsen BE; Anderson JL; Lien KR; Sutor SL; Lee JS; Thorgeirsson SS; Grande JP; Roberts LR; Woodrum DA
PLoS One; 2016; 11(9):e0162634. PubMed ID: 27611696
[TBL] [Abstract][Full Text] [Related]
37. Targeting of mTORC2 may have advantages over selective targeting of mTORC1 in the treatment of malignant pheochromocytoma.
Zhang X; Wang X; Xu T; Zhong S; Shen Z
Tumour Biol; 2015 Jul; 36(7):5273-81. PubMed ID: 25666752
[TBL] [Abstract][Full Text] [Related]
38. A functional mammalian target of rapamycin complex 1 signaling is indispensable for c-Myc-driven hepatocarcinogenesis.
Liu P; Ge M; Hu J; Li X; Che L; Sun K; Cheng L; Huang Y; Pilo MG; Cigliano A; Pes GM; Pascale RM; Brozzetti S; Vidili G; Porcu A; Cossu A; Palmieri G; Sini MC; Ribback S; Dombrowski F; Tao J; Calvisi DF; Chen L; Chen X
Hepatology; 2017 Jul; 66(1):167-181. PubMed ID: 28370287
[TBL] [Abstract][Full Text] [Related]
39. mTOR Ser-2481 autophosphorylation monitors mTORC-specific catalytic activity and clarifies rapamycin mechanism of action.
Soliman GA; Acosta-Jaquez HA; Dunlop EA; Ekim B; Maj NE; Tee AR; Fingar DC
J Biol Chem; 2010 Mar; 285(11):7866-79. PubMed ID: 20022946
[TBL] [Abstract][Full Text] [Related]
40. Phosphorylation of mTOR Ser2481 is a key target limiting the efficacy of rapalogs for treating hepatocellular carcinoma.
Watari K; Nishitani A; Shibata T; Noda M; Kawahara A; Akiba J; Murakami Y; Yano H; Kuwano M; Ono M
Oncotarget; 2016 Jul; 7(30):47403-47417. PubMed ID: 27329724
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
